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Abstract
A high percentage of patients with the myeloproliferative disorder polycythemia vera (PV) harbor a Val617RPhe activating
mutation in the Janus kinase 2 (JAK2) gene, and both cell culture and mouse models have established a functional role for
this mutation in the development of this disease. We describe the properties of MRLB-11055, a highly potent inhibitor of
both the WT and V617F forms of JAK2, that has therapeutic efficacy in erythropoietin (EPO)-driven and JAK2V617F-driven
mouse models of PV. In cultured cells, MRLB-11055 blocked proliferation and induced apoptosis in a manner consistent with
JAK2 pathway inhibition. MRLB-11055 effectively prevented EPO-induced STAT5 activation in the peripheral blood of
acutely dosed mice, and could prevent EPO-induced splenomegaly and erythrocytosis in chronically dosed mice. In a bone
marrow reconstituted JAK2V617F-luciferase murine PV model, MRLB-11055 rapidly reduced the burden of JAK2V617F-
expressing cells from both the spleen and the bone marrow. Using real-time in vivo imaging, we examined the kinetics of
disease regression and resurgence, enabling the development of an intermittent dosing schedule that achieved significant
reductions in both erythroid and myeloid populations with minimal impact on lymphoid cells. Our studies provide a
rationale for the use of non-continuous treatment to provide optimal therapy for PV patients.
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Introduction
Polycythemia vera (PV), essential thrombocythaemia (ET) and
primary myelofibrosis (PMF) are all conditions that are classified as
‘‘Philadelphia-chromosome negative chronic myeloproliferative
disorders’’. PV is one of the more prevalent, afflicting an estimated
65,000 patients in the United States alone [1], and is associated
with splenomegaly, erythrocytosis, thrombocytosis and leukocyto-
sis. Standard of care treatment for PV is phlebotomy supplement-
ed with low-dose aspirin, and for intermediate to high risk patients
follow-up hydroxyurea can be prescribed [2,3]. While these
treatment regimens have provided an excellent survival benefit,
patients still suffer from reduced quality of life, owing to chronic
fatigue, pruritis and bone pain [4]. Additionally patients are at
significant risk of transformation to hematological malignancies
such as AML.
In 2005, several groups independently discovered a somatic
mutation of the gene encoding JAK2 in a high percentage (.95%)
of patients with PV, and to a lesser extent, ET and PMF [5–9]. A
single valine to phenylalanine mutation at position 617, located in
a pseudokinase domain thought to negatively regulate the adjacent
kinase domain, results in increased JAK2 autophosphorylation,
and subsequent activation of downstream signaling networks.
Mutation of JAK2 confers cytokine-independent proliferation and
survival of a previously EPO-dependent cell line, consistent with
its role in mediating erythropoietin (EPO) signaling. Remarkably,
reconstitution of irradiated mice with transduced bone marrow
expressing JAK2V617F leads to a condition that strongly resembles
PV within 4–6 weeks, with overt erythrocytosis, splenomegaly, and
in some strains of mice, leukocytosis [10–12]. Treatment with
JAK2 inhibitors can attenuate these symptoms[13–15], thus, there
is genetic, cell based, and in vivo evidence to suggest a functional
role for mutant JAK2 in the pathology of PV, and it is reasonable
to predict that targeting the JAK2 protein could have therapeutic
benefit in this patient population.
In fact, the MPD community has been eagerly anticipating the
development of JAK inhibitors, and several are currently being
tested in clinical trials [16–18]. Given the broad role of JAK
kinases in hematopoiesis, a key challenge will be not only the
discovery of high quality targeted agents, but also effective
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be problematic. We have recently reported the discovery of a
potent, orally active inhibitor of JAK2 [19]. In this study we report
the biological characterization of this inhibitor (MRLB-11055) and
its use to identify a safe and efficacious dosing schedule in a
JAK2
V617F-dependent model of PV.
Materials and Methods
1. Reagents, Cell Lines, Ethics Statement
MRLB-11055 was synthesized as described previously [20].
Antibodies used were as follows. Phospho-STAT3 (Tyr705)
D3A7 rabbit monoclonal antibody, Cell Signaling Technology
(CST) #9145. STAT3 rabbit polyclonal antibody, CST #9132.
Phospho-Src Family (Tyr416) rabbit polyclonal antibody, CST
#2101. Polysorbate 80, Fluka. PEG400, Sigma Aldrich. HPbCD,
Cyclodextrin Technologies Development Holdings.
BaF3 cells were obtained from the laboratory of Dr. Gary
Gilliland, Brigham & Women’s Hospital. All cell lines were
obtained from ATCC. All animal studies were performed
according to approved protocols by Merck Boston’s Institutional
Animal Care and Use Committee (06-04-019; 07-04-033; 08-04-
032).
2. In vitro Assays
2.1. JAK enzyme assays. JAK1, JAK2, JAK3, and TYK2
kinase activity assays were performed as described previously [21]
using HTRF detection technology and the peptide substrate
amino hexanoyl biotin-EQEDEPEGDYFEWLE-NH2. Each re-
action was incubated between 60 and 80 min at room temper-
ature. Final conditions were as follows: JAK1, 400 pM enzyme,
Hepes pH 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA,
0.1 mg/ml BSA), 2 mM DTT, 2 mM peptide substrate, 25 mM
MgATP, 5% DMSO and the desired concentration of subject
compound; JAK2, 25 pM enzyme (JH1, JH1–JH2
wt, JH1–
JH2
V617F domains), 2 mM peptide substrate, 15 mM MgATP,
5 mM MgCl2, 100 mM NaCl, 2 mM DTT, 0.1 mg/ml BSA,
50 mM Tris (pH 7.4), 5% DMSO and the desired concentration
of subject compound; JAK3, 250 pM enzyme, 50 mM Hepes
pH 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.1 mg/ml
BSA), 2 mM DTT, 2.0 mM peptide substrate, 25 mM MgATP,
5% DMSO, and the desired concentration of subject compound;
TYK2, 125 pM enzyme, 50 mM Hepes pH 7.5, 10 mM MgCl2,
0.01% Brij-35, 1 mM EGTA, 0.1 mg/ml BSA, 2 mM DTT,
2.0 mM peptide substrate, 15 mM MgATP, 5% DMSO and the
desired concentration of subject compound.
Kinase profiling was conducted by Millipore (Billerica, MA).
2.2. Cell phosphoprotein assays. Measurement of
pSTAT5 in cells was performed essentially as described previously
[21] using an AlphaScreen
TM SureFire
TM (Perkin Elmer) assay.
BaF3 (JAK2 WT), BaF3 (JAK2 V617F), and CTLL-2 cells were
exposed to compound for 60 min prior to lysis and subsequent
detection of pSTAT5 via AlphaScreen technology. Prior to
compound treatment, BaF3 (JAK2 WT) and CTLL-2 cells were
cytokine starved overnight, with EPO or IL-2 added 15 minutes
prior to lysis, respectively.
Phosphorylated and unphosphorylated forms of STAT3 were
measured by Western Blot. A549 cells (600,000) were treated with
inhibitor for 45 minutes, then stimulated with IL-6 (10 ng/mL) for
15 minutes. Cells were lysed in 30 mM Tris (pH7.5), 5 mM
EDTA, 50 mM NaCl, 30 mM NaPPi, 50 mM NaF, 0.5%
IGEPAL, 1% Triton, 10% Glycerol, 1 complete Protease
Inhibitor Cocktail Tablet, mini (Roche), and 1 PhosSTOP
Phosphatase Inhibitor Cocktail Tablet (Roche). Proteins (50 mg)
were seperated with a 7.5% SDS-PAGE gel, and transferred onto
a nitrocellulose membrane. Proteins were detected using antibod-
ies described in the Materials section, as per the manufacturer
protocol.
2.3. Cell phenotypic assays. Cell proliferation was mea-
sured by ViaLight (Lonza Group Ltd) assay as follows. Cells
(1000–2000) were seeded into 384-well plates and incubated 16
hours @ 37uC, 5% CO2. Inhibitors (dissolved in DMSO) were
added such that the final concentration of DMSO did not exceed
0.25%, and cells were further incubated for 48–72 hrs. Cells were
lysed and ATP detected as per the manufacturer protocol.
Cell survival was measured by ApoDirect (BD Biosciences) assay
as follows. BaF3 cells were grown at 37uC, 5% CO2, and aliquots
(2 6 10
6) were treated with inhibitor (various concentration
dissolved in DMSO) for 24 hours and then fixed and stained as per
manufacturer protocol.
2.4 Human Progenitor Colony Formation Assays. Assays
were conducted by Stem Cell Technologies Inc. using Metho-
Cult
TM
media (methylcellulose-based media containing cytokines)
with or without EPO. MRL-11055 was added to media at the
specified concentrations, and cells (from either normal donors or
PV patients) were then added at a density optimized for colony
formation. Each condition was plated into triplicate plates and
incubated at 37uC, 5% CO2. Following 14 days in culture, the
colonies were assessed and scored based on size and morphology.
All samples were obtained anonymously.
3. Darbepoetin-Induced Model of PV
3.1. Formulation and Dosing of MRLB-11055. C57BL/6
mice (Charles River Laboratories, Wilmington, MA) aged 4–6
weeks were dosed with MRLB-11055 in vehicle (10%v/v
polysorbate 80) or with vehicle alone. All dosing was done by
oral gavage (10 ml/kg body weight/day).
3.2. Acute PK/PD. Blood sampling and measurement of
pSTAT5 in the blood of darbepoetin-stimulated mice were
measured as described previously [22]. The level of MRLB-
11055 in the blood of animals was measured by diluting blood
samples (10 uL) with citrate buffer (30 uL) and precipitating with
acetonitrile (200 uL) containing a structural analog as internal
standard. Precipitated samples were filtered, water (200 uL) was
added and the sample injected onto a C18 column (Waters Atlantis
T3, 2.1 mm x 30 mm). Electrospray ionization with multiple
reaction monitoring was used for MS/MS detection.
3.3. Efficacy Endpoints
Inhibition of darbepoetin-induced polycythemia and spleno-
megaly by MRLB-11055 was measured as described previously
[22].
4. Bone Marrow Transplant Mice Expressing JAK2
V617F-
Luciferase
4.1. Viral Production and Bone Marrow
Transplantation. Production of retrovirus containing cDNA
of JAK2 V617F fused to luciferase 2 was performed as described
previously [23] as was transplantation of bone marrow cells
infected with virus into irradiated mice.
4.2. Bioluminescence Imaging (BLI). Imaging of mice
expressing JAK2 V617F-Luciferase was conducted as described
previously [23].
4.3. JAK2 V617F allele-specific real-time
PCR. Measurement of the level of JAK2 V617F allele in the
tissues of transplanted mice was done as described previously [23].
Intermittent Dosing of a Novel JAK2 Inhibitor
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Cells were stained in PBS, 0.5% BSA with antibodies for 15 min
on ice. Stained cells were acquired on a 4-laser LSR-II (BD
Biosciences) and data analyzed using FlowJo software (Treestar).
Dead cells were labeled with the blue fluorescent LIVE/DEAD
reactive dye (Invitrogen) and excluded from the analysis.
Monoclonal antibodies (anti-mouse): CD3, CD4, CD5, CD8,
CD11b, CD19, CD21/35, CD23, CD25, CD43, CD44, CD49b,
CD69, CD71, CD93, CD117, B220, GR-1, IgD, NK1.1,
NKG2A/C/E, NKG2D, Ter119 were purchased from BD
Biosciences; CD4, CD8, CD49b, CD62L, TCRb, TCRcd from
eBioscience; GR-1 from Invitrogen; CD43 from Miltenyi Biotec.
Goat anti-mouse IgM-FITC, (m chain specific) from Jackson
Immuno Research.
Results
In vitro Properties of MRLB-11055
MRLB-11055 (Figure 1A) potently inhibits the ability of both
wild-type JAK2 (JAK2
WT) and mutant JAK2 (JAK2
V617F)t o
phosphorylate a peptide substrate in cell-free assays (Table 1).
MRLB-11055 inhibits the JH1 kinase domain in an ATP-
competitive manner (data not shown), and therefore binds to
the ATP-binding pocket of JAK2. In the IL-3 dependent BaF3
cell line, expression of both EPO receptor and either WT or
V617F JAK2 kinase, causes proliferation to become dependent
on EPO (JAK2
WT case) or independent of growth factor
(JAK2
V617F case), respectively [8]. MRLB-11055 potently
inhibited proliferation in both of these engineered cell lines
(Table 1, Figure 1B), in a manner that correlated closely with
inhibition of phosphorylation of the JAK2 substrate, STAT5
(Table 1, Figure 1C). As seen in the cell-free assays, MRLB-
11055 had similar potency against both the mutant and WT
form of JAK2 in BaF3 cell proliferation assays. This indifference
was also observed for inhibition of colonies formed from the
blood of PV patients and from healthy donors (Figure S1). In
TUNEL assays that measure apoptosis, however, JAK2
V617F-
expressing cell lines demonstrate significantly greater response to
MRLB-11055 than their WT counterpart (Figure 1D). Taken
together, MRLB-11055 is a potent inhibitor of both JAK2
WT
and JAK2
V617F in both cell-free and cell-based assays, and there
is evidence that JAK2
V617F cells are more dependent on the
activated JAK2 pathway for survival.
Selectivity of MRLB-11055 was assessed against recombinant
JAK family members using a variety of methods (Table 1). In cell-
free assays, MRLB-11055 demonstrated excellent selectivity for
JAK2 over JAK3 (.3000-fold), while selectivity over JAK1 and
Tyk2 was more limited (20-fold and 2-fold, respectively). In
CTLL-2 cells, IL-2 stimulation leads to phosphorylation of
STAT5 via both JAK1 and JAK3. MRLB-11055 inhibited this
activity with an IC50 of 66 nM, 6-times less potently than the
inhibition of JAK2
V617F-mediated pSTAT5 in BaF3 cells.
However, in proliferation assays, MRLB-11055 was actually 2-
fold more potent against the IL-2-dependent CTLL cells than the
JAK2
V617F BaF3 cells, consistent with a greater functional
dependence on JAK-STAT signaling in this T-lymphocyte derived
cell line. MRLB-11055 was also tested for its ability to inhibit a
broad panel of recombinant kinases in cell-free assays. Of the 220
tested kinases, JAK2 was the most potently inhibited, and 198
kinases yielded an IC50 value that was greater than 25-fold of the
JAK2 IC50. Among these off-target kinases were several Src-kinase
family members (Table S1). To assess the consequence of the
inhibition of these 22 kinases (and potentially other cellular kinases
that are not available for cell-free assay), we tested the effect of
MRLB-11055 on the proliferation of several lung epithelial cancer
cell lines, including H2122 cells (Table 1). On average, the IC50
for inhibition of these lines was 50–70-fold higher than for JAK2-
dependent cell lines. We conclude that MRLB-11055 has good
JAK2 selectivity that specifically inhibits growth of JAK2
dependent cell lines and is suitable to perform therapeutic efficacy
experiments in vivo.
Effect of MRLB-11055 on JAK2 Pathway Activity in vivo
We have previously established that C57BL/6 mice injected
with the EPO analog darbepoetin display elevated levels of
pSTAT5 in the peripheral blood [22]. To assess the ability of
MRLB-11055 to inhibit EPO signal transduction pathways in
vivo, we orally administered compound to C57BL/6 mice that
had been simultaneously injected with darbepoetin and mea-
sured pSTAT5 levels in blood over time. As shown in
Figure 2A, pSTAT5 was reduced in a dose-proportional
manner, and .90% inhibition was maintained over 12 hours
at a dose of 36 mg/kg (mpk). The IC50 for MRLB-11055 in
this system was determined to be 1.2 mM (Figure 2B). MRLB-
11055 demonstrated dose-proportional exposure in the periph-
eral blood of mice, and at 36 mpk we predict that MRLB-
11055 remains above the pSTAT5 IC50 for approximately 16
hours (Figure 2C).
Effect of MRLB-11055 on Darbepoetin-Induced Model of
Polycythemia
Mice repeatedly administered the EPO analog darbepoetin
develop erythrocytosis and splenomegaly – both major diagnostic
criteria for PV - over a period of 7 days [22]. The effectiveness of
MRLB-11055 in preventing the development of the polycythemic
phenotype was assessed by orally administering drug once daily at
doses of 5, 15, 25 and 40 mpk and comparing disease endpoints to
that of mice given only vehicle and mice not given any
darbepoetin (Figure 3). Elevated hematocrit (Hct) and spleen
weight (SPL) were prevented in a dose-dependent manner, with
the highest dose achieving efficacy levels of 76% and 87%,
respectively. MRLB-11055 demonstrated dose dependent expo-
sure in the blood that correlated with its effect on the polycythemic
phenotype. At the highest dose of 40 mpk, MRLB-11055 achieved
a concentration equal to about 10 times its in vivo pSTAT5 IC50
value, when measured one hour after administration on the last
day of the experiment. MRLB-11055 demonstrated a dose-
dependent trend towards WBC reduction, that did not reach
statistical significance. Thus, MRLB-11055 was effective at
preventing acute development of a PV-like disease driven by
wild-type JAK2.
Effect of MRLB-11055 on JAK2
V617F-Luciferase Expressing
Cells in Bone Marrow Transplant Mice
We have previously described a model of PV in which
lethally irradiated mice receive bone marrow that co-expresses
JAK2
V617F with luciferase [23]. These mice develop a robust
PV phenotype 4 weeks after transplantation and cells expressing
the transduced genes, which can be monitored in real-time with
bioluminescent imaging methodology, are observed to expand
rapidly in hematopoetic compartments, particularly the spleen.
To determine the effect of MRLB-11055 on JAK2
V617F-
expressing cells in this model system, we orally administered
drug once daily at a dose of 54 mpk for 3, 5 and 7 days, and
examined bioluminescent intensity (BLI) and erythroid progen-
itor cells, identified as CD71
+TER119
+ in spleen, as well as
V617F allele burden (measured by qPCR) in peripheral blood
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observed at the earliest timepoint of Day 3, with no further
benefit from additional days of treatment out to Day 7. Similar
reductions in BLI were observed in bone marrow and in lateral
side of the mouse, including spleen (data not shown). We also
examined the correlation between BLI and CD71
+TER119
+
cells in individual mice treated with MRLB-11055. Figure 4B
demonstrates a good correlation between these two endpoints,
suggesting that BLI (repeatedly available from a given mouse) is
a good methodology for repeated measurements and surrogate
for splenic erythoid progenitor fraction size (whose measurement
requires sacrifice of the mouse). We further measured the effect
of cessation of MRLB-11055 treatment on spleen BLI in mice
treated once daily for 7 days. As shown in Figure 4C, some
recovery of JAK2
V617F-expressing cells was observed, however
the recovery was slow and remained below pre-treatment levels.
As shown in Figure 4D, the level of pSTAT5 in spleens of
JAK2
V617F-Luciferase mice was significantly inhibited by
MRLB-11055 (1 hour post-dose), consistent with the observed
effects on BLI, erythroid progenitors and JAK2
V617F. These
experiments collectively demonstrate that MRLB-11055 is
effective at treating early efficacy endpoints in a JAK2
V617F -
driven model of PV.
Effect of Multi-cycle Intermittent Dosing of MRLB-11055
on PV Phenotype in BMT Mice Expressing JAK2
V617F-
Luciferase
Having established that 3 days of once daily treatment with
MRLB-11055 significantly impacts JAK2
V617F-expressing cells,
with partial resurgence of these cells upon termination of
treatment, we next examined the effect of multiple cycles of
intermittent dosing of this inhibitor on the PV phenotype in
JAK2
V617F-Luciferase BMT mice. Each cycle consisted of oral
administration of 54 mpk once daily for 3 days, followed by a 4
day holiday. Mice were treated with 2 cycles of this regimen upon
completing their 3
rd week post-transplant, at a time when BLI and
CD71
+TER119
+ cells in the spleen had reached a plateau, and
mice were mildly polycythemic, but hematocrit was still in the
process of increasing. When treated in this way, the spleens of mice
demonstrated a significant reduction (,20-fold) in BLI over the
first 3 days of treatment. BLI subsequently increased nearly 4-fold
over the next 4 days, but it remained about 5-fold less than pre-
treatment levels (Figure 5A). The second cycle of treatment and
holiday resulted in levels that were similar to those obtained with
the first cycle. In comparison, the BLI levels in the spleen of
vehicle treated mice decreased slightly over these two cycles
(Figure 5B). Hematocrit levels in vehicle treated mice increased
Figure 1. Effect of MRLB-11055 on JAK2-dependent cell lines grown in vitro. A. Structure of MRLB-11055. B. Effect on proliferation of BaF3
JAK2 V617F cells over 48 hours. C. Effect on phosphoSTAT5 levels in JAK2-expressing BaF3 cells. D. Effect of 75 nM MRLB-11055 on level of apoptosis
in BaF3 JAK2 cells over 48 hours.
doi:10.1371/journal.pone.0037207.g001
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In mice treated with MRLB-11055, however, hematocrit de-
creased from 53% to 42%. Reductions in hematocrit occurred
during both administration and holiday phases of the cycle. At the
end of the second holiday period, mice demonstrated a significant
reduction in CD71
+TER119
+ cells in spleen relative to vehicle
controls, as well as normalization in spleen weight (Figure 5D).
Similar results were obtained when mice were treated for 4-cycles
(Figure S2), demonstrating that intermittent dosing can be
efficacious over prolonged periods of time. Thus, MRLB-11055
effectively impacted clinically relevant endpoints in a JAK2
V617F-
dependent model of PV.
Effect of MRLB-11055 on Major Lymphoid Populations in
WT Mice
JAK2 and its family members JAK1 and JAK3 are known to
signal downstream of cytokines that play essential roles in the
development of lymphoid cell populations [24]. To examine more
thoroughly the effects of JAK2 inhibition on lymphoid cells, we
analyzed wild-type (C57BL/6) mice treated with 54 mpk MRLB-
11055 for 3 days, 6 days or up to 5 cycles of 3 days (‘‘on’’) followed
by a 4 day holiday (‘‘off’’).
Flow cytometric analysis of splenic populations such as NK cells
(NK1.1
+CD49b
+), CD4
+ T-cells (CD3
+CD4
+), CD8
+ T-cells
(CD3
+CD8
+) and B-cells (B220
+) revealed a time-dependent
decrease of B and T lymphocytes, as well as NK cells, ranging
from 2-fold (B220
+) to 25-fold (NK1.1
+ cells) over 6 days of
continuous treatment with the inhibitor (Figure 6 and Table S2).
Intermittent dosing however, when administered for 5 cycles of 3
Table 1. In vitro Profile of MRLB-11055.
Category Activity IC50 (nM)
a
Cell-free JAK2
b JAK2 (JH1)
WT 0.08
JAK2 (JH1–JH2)
WT 0.78
JAK2 (JH1–JH2)
V617F 0.35
Cell pSTAT5
c
(1 hour)
BaF3
d (JAK2 WT) 23
BaF3 (JAK2 V617F) 11
CTLL-2
e 66
Cell Proliferation
f
(48 hour)
BaF3
d (JAK2 WT) 14
BaF3 (JAK2 V617F) 29
CTLL-2
f 13
H2122
g 1900
Cell Apoptosis
h
(24 hour)
BaF3
d (JAK2 WT) 260
BaF3 (JAK2 V617F) 135
Cell-free Kinase Selectivity TYK2 (JH1) 0.18
JAK1 (JH1) 1.5
JAK3 (JH1) 300
198/220 kinases
i .25-fold over
JAK2
a) Mean value, n=3.
b) Kinase activity, HTRF assay.
c) pJAK2 and pSTAT5 activity measured via AlphaScreen and BeadLyte assays.
d) EPO-stimulated.
e) IL2-stimulated CTLL-2 cells, JAK1 and JAK3 dependent.
f) Cell growth, Vialight assay.
g) Epithelial lung cancer cell line.
h) Apoptosis determined by ApoDirect measurement of fragmented DNA.
Values shown are EC50.
i) See Table S1 for all kinases within 25-fold. Fold selectivity based on JAK2 (JH1-
JH2) IC50.
doi:10.1371/journal.pone.0037207.t001
Figure 2. Exposure and target engagement of MRLB-11055 in
the peripheral blood of C57BL/6 mice stimulated with darbe-
poetin. A. Effect of MRLB-11055 on phosphoSTAT5 levels at various
times post-dose. B. Calculation of IC50 value for inhibition of
phosphoSTAT5. C. PK of 3 doses of MRLB-11055 in mouse blood, with
calculated IC50 superimposed (dashed line).
doi:10.1371/journal.pone.0037207.g002
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exceeding 2-fold for any of the lymphocytes tested.
Analysis of peripheral blood showed that long-term intermittent
inhibition of JAK2 resulted in a lower hematocrit in C57BL/6
mice (Table S3). Consistent with this observation, red blood cell
counts and hemoglobin concentrations were lower in the treated
animals. The CD71
+Ter119
+ erythroid progenitor population in
spleen and the reticulocyte count in blood was effectively reduced
during MRLB-11055 treatment and recovered quickly during the
off-phase, likely in response to the lowered HCT values in treated
animals (Tables S2 and S3). JAK2 inhibition did not alter the
number of neutrophils but interestingly resulted in an increase of
blood platelets.
Similar and consistent results were obtained when analyzing
lymphocyte development and erythroid progenitor populations in
bone marrow and thymus (Tables S4, S5). These data demonstrate
that intermittent dosing of MRLB-11055, at a dose level that was
effective at reducing hematocrit and normalizing spleen weight in
JAK2
V617F mice, was sparing of lymphocyte populations in normal
C57BL/6 mice.
Discussion
Polycythemia vera (PV) is a disease involving biology for which
there is a rich history of study. The discovery of the JAK
V617F
mutation shed light on the mechanism of disease origin and
development.However,fromthepublishedliteratureitappearsthat
while JAK2 certainly plays an important role, other elements also
likely contribute to the pathological evolution of PV [7,25]. What is
notknowniswhetherinhibitionoftheconstitutivelyactivatedJAK2
mutant, signaling aberrantly downstream of the EPO receptor in
erythroid and myeloid progenitor cells, will provide an effective
improvement in the treatment of PV patients. To that end, several
groups have developed pre-clinical models of PV disease [10–
12,26], enabling the development of JAK2 inhibitors for evaluation
in the clinic. A major challenge in development of any JAK2
inhibitorthatisnotselectivefortheV617Fformoftheenzymeisthe
expected mechanism-based toxicity, as JAK2 signaling is essential
for many biological processes, within the hematopoeitic compart-
ment and beyond [27,28]. Chronic, high-level inhibition of JAK2
would almost certainly be intolerable, even if only considering the
intended target tissues of the erythroid and myeloid lineage. Thus
the dosing schedule of a JAK2 inhibitor is likely to be an important
consideration in addition to the intrinsic properties of that inhibitor
when considering its potential for successful clinical application.
MRLB-11055 is a potent inhibitor of JAK2, however, similar to
other described inhibitors of JAK2, it is not selective for
JAK2
V617F over JAK2
WT. Despite this lack of selectivity at the
enzyme level, cells that are dependent on JAK2
V617F for growth
are much more likely to commit to apoptosis in the presence of
MRLB-11055 than their WT counterparts. This suggests a
potential problem of adverse effects arising from chronic systemic
JAK2 inhibition, and set the stage for exploring intermittent
dosing in vivo. The pharmacokinetics of MRLB-11055 in mice was
such that we were able to achieve sustained target inhibition each
dosing cycle with once daily dosing, enabling efficacy studies. As
MRLB-11055 was potent against JAK2
WT, we were able to
demonstrate efficacy in a model where PV-like symptoms, such as
erythrocytosis and splenomegaly, could be rapidly generated by
treatment of normal C57BL/6 mice with darbepoetin. While an
Figure 3. Effect of MRLB-11055 in a Darbepoetin-Induced PV Efficacy Model. The ability of MRLB-11055 to prevent darbepoetin-induced
increases in hematocrit (Hct) and spleen mass (SPL) over 7 days is shown, as is the impact of MRLB-11055 on white blood cells (WBC) and its
concentration in blood (PK). Dashed line indicates in vivo IC50 value.
doi:10.1371/journal.pone.0037207.g003
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preventative, and thus did not allow the interrogation of dosing
scheme in the context of an established disease state.
Several mouse models of PV have been described that employ
bone marrow transplantation of JAK2
V617F to generate a
phenotype that bears many of the hallmarks of disease. In all of
these models, there is not only an expansion of erythrocytes, but
also an expansion of the erythroid progenitor cells, which are their
EPO receptor-expressing predecessors. PV patients are known to
suffer from an increase in these cells, which appear as endogenous
erythroid colonies (eEECs) in ex-vivo soft agar assays. In order to
evaluate not only the effectiveness of an inhibitor but the optimal
dose and schedule of that inhibitor, we reasoned that this
progenitor population was the most likely candidate for the direct
target tissue for the drug, and hence a key readout. Erythrocytes,
as descendants of these cells, are indirectly targeted and with an
inherent latency due to their lengthy half-life. Monitoring
erythroid progenitors, however, is not readily achieved, and
presents a challenge for assessment of optimal treatment time and
holiday when developing a dosing schedule. For these reasons, we
developed a JAK2
V617F-Luciferase model system that allows real-
time imaging of mutant expressing cell populations, which includes
the erythroid progenitor population. A key consideration in the
use of this model was the most appropriate stage in the progression
of disease for introduction of the JAK2 inhibitor. We chose to
administer the inhibitor to the mice at end of the 3rd week post-
BMT, at which time they were mildly polycythemic, with
hematocrit levels actively rising. This state most closely models
the clinical condition of PV patients, who are not allowed to
achieve plateau levels of Hct in normal care, and exist in a state of
rising hematocrit between phlebotomy treatments.
Under these conditions MRLB-11055 was observed to dramat-
ically reduce the level of both erythroid progenitor cells and BLI in
the spleen within a 3 day treatment period. While the exact
mechanism of this reduction is not known, it is consistent with the
rapid and robust induction of apoptosis in BaF3 cells dependent
on JAK2
V617F in vitro. When MRLB-11055 was removed, V617F-
expressing cells immediately began to re-expand, consistent with
the previous observation that the JAK2 mutation penetrates into
the hematopoeitic stem cell population in these mice [23]. Based
on these observed kinetics of reduction and re-expansion, we were
able to devise a multi-cycle intermittent dosing scheme aimed at
normalizing progenitor populations. Application of this scheme
not only prevented further rise of hematocrit in these mice, but
actually decreased hematocrit to a level below the normal range.
These decreases occurred even during the drug holiday period,
clearly demonstrating that JAK inhibition need not be continuous
to result in significant efficacy, and that hematocrit levels can be
Figure 4. Effect of MRLB-11055 on Target Tissue in JAK2 V617F-Luc2 Mice. A. Time dependence of the effect of 54 mpk MRLB-11055 on key
V617F-dependent endpoints. B. Correlation between BLI and CD71+TER119+ in spleen on Day 14 C. BLI recovery after treatment cessation on Day 7.
D. Effect of MRLB-11055 on pSTAT5 in the spleen of V617F mice.
doi:10.1371/journal.pone.0037207.g004
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erythroid progenitor populations.
JAK inhibitors have been described to have potent effects on
lymphocyte subpopulations [29,30], prompting us to examine
these lineages more closely. MRLB-11055 did indeed reduce T, B
and NK cell fractions in the spleens of normal C57BL/6 mice
when administered continuously at high doses. However, these
reductions were significantly alleviated when MRLB-11055 was
given intermittently according to the efficacious dosing schedule in
the JAK2
V617F-Luciferase mouse model. As immune function
depends on the presence of these lymphoid cells, this data suggests
that intermittent dosing could minimize immunodeficiencies
induced by treatment with a JAK2 inhibitor.
We recognized that MRLB-11055 had modest selectivity for
signaling induced by EPO/JAK2 over signaling induced by IL-2/
JAK1/JAK3, a pathway known to play a role in lymphocyte
development.Furthermore,MRLB-11055hadlittletonoselectivity
forJAK2overSrc-familykinasesandFlt-3(TableS1),whicharealso
keymediatorsinthematurationoflymphocytes.Toaddressthis,we
evaluated the effect of a structurally distinct JAK2 inhibitor with
enhanced selectivity over these other signaling molecules. At
exposuresthatresultedincomparableefficacytoMRLB-11055,this
inhibitor demonstrated identical reductions in lymphocyte popula-
tions(unpublisheddata).Oneexplanationforthesefindingsisthatthe
reductioninthesecellpopulationsisdue,atleastinpart,toinhibition
of JAK2 itself, which is consistent with a role of JAK2-dependent
cytokines such as IL-12 in lymphocyte development. We have
demonstrated that intermittent dosing can attenuate many of the
undesirableeffectsthatwilllikelybeassociatedwiththeuseofJAK2
inhibitors in the treatment of MPD. In addition to signaling
downstream of the EPO receptor, JAK2 plays a role in mediating
signaling from a variety of molecules, including IFNc, IL-6, TPO,
GM-CSF, prolactin, growth hormone, and angiotensin 1.
The JAK2inhibitorTG101348has beendescribed asa molecule
that is both efficacious in a murine model of PV and sparing of T
lymphocytes [14]. While inhibition of pSTAT5 was clearly demon-
strated 2 hours after TG101348 administration, it is not clear how
prolonged target inhibition was during dosing. As TG101348
required 42 days of continuous treatment to achieve hematocrit
reductionsof18%,itisreasonabletopresumethattargetengagement
may have been lower relative to MRLB-11055 for a given dosing
cycle. Thus the apparently unperturbed T lymphocyte populations
Figure 5. Effect of 2 Cycles of Intermittent Dosing (3 days on, 4 days off) of MRLB-11055 on V617F-Luc2 Mice (N=10). Effect on A & B.
Bioluminescence in spleen C. Hematocrit D. Multiple endpoints at end of study (Day 14).
doi:10.1371/journal.pone.0037207.g005
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NK cells, which responded most sensitively to MRLB-11055
inhibition, was not measured withTG101348.
We have demonstrated that intermittent dosing of a JAK2 inhibitor
can effectively normalize erythroid progenitor populations and
thereby effectively treat conditions of polycythemia and splenomegaly
in mouse models of PV. Our data can provide signficant guidance to
the clinical development of JAK2 inhibitors. While the kinetics of
erythropoesis are likely different in human disease, our data provide
proof-of-concept for the use of erythroid progenitor populations as
early biomarkers of target tissue efficacy, that could guide develop-
ment of optimized intermittent dosing schemes to provide patients
with improved therapy. Furthermore, our data show that lymphoid
populations, in particular NK cells, serve as sensitive biomarkers for
JAK inhibitor toxicity that is potentially mechanism-based.
Supporting Information
Figure S1 Effect of MRLB-11055 on Human Progenitor
Cell Growth Ex-vivo. A. Effect of dose on colony number. B.
Summary of IC50 values across 3 patient samples. C. Represen-
tative micrograph of effect on colony growth.
(TIF)
Figure S2 Effect of 4 Cycles of Intermittent Dosing (3
days on, 4 days off) of MRLB-11055 on V617F-Luc2 Mice
(N=10). Effect on A & B. Bioluminescence in spleen C.
Hematocrit D. Multiple endpoints at end of study (Day 28).
(TIF)
Table S1 Recombinant Kinase Selectivity Profile of
MRLB-11055. IC50s measured at ATP Km, and fold increase
relative to JAK2 is reported.
(DOC)
Table S2 Effect of MRLB-11055 on Cell Populations in
Spleen of Normal Mice. Cell counts measured by
Advia. Cycles refer to 3 days of treatment followed by a 4
day holiday. *p,0.05 in Student T test when comparing vehicle
5 cycle with treatment 5 cycle and vehicle 2 cycle with treatment
2c y c l e ,r e s p .
(DOC)
Table S3 Effect of MRLB-11055 on Cell Populations in
Peripheral Blood of Normal Mice. Cell counts measured by
Advia. Cycles refer to 3 days of treatment followed by a 4 day
holiday. *p,0.01 and **p,0.001 in Student T test when
Figure 6. Effect of MRLB-11055 on major lymphoid populations in spleen of WT B6 mice. MRLB-11055 was given for either 3 or 6 days
(on), followed up by either a 0 or 4 day holiday (off), for up to 4 cycles. Effects on NK, B and T cells were measured by flow cytometry.
doi:10.1371/journal.pone.0037207.g006
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Table S4 Effect of MRLB-11055 on Cell Populations in
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Table S5 Effect of MRLB-11055 on Cell Populations in
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